评估罕见疾病的理解:一种新型疾病准备水平框架
Kazuki Kitahara1, Shingo Kano2
1Bio-Innovation Policy Unit, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa-shi, , Chiba, 2778562, Japan. kk237341@stu-cbms.k.u-tokyo.ac.jp.
Orphanet journal of rare diseases
|December 30, 2025
概括
一个新的疾病准备水平 (DRL) 框架评估罕见疾病的理解和药物开发进展. 该工具有助于优先考虑罕见疾病的研究和资源分配.
科学领域:
- 医学研究 医学研究
- 罕见疾病研究研究.
- 药物开发 药物开发
背景情况:
- 由于市场规模较小,为罕见疾病开发药物面临着优先考虑的挑战.
- 对于孤儿药物的现有激励政策缺乏对资源分配的确立评估方法.
- 需要方法来衡量罕见疾病的理解,并将其与其他疾病进行比较,以促进研发.
研究的目的:
- 提出一种分级系统,即疾病准备水平 (DRL),用于同时测量罕见疾病的理解和产品开发进展.
- 建立一个框架,以帮助评估需要资源支持的罕见疾病.
主要方法:
- 调整了国家航空航天局的技术准备水平 (TRL) 框架,以创建DRL.
- 包括临床指导方针和扩展评估到比传统产品开发更早的阶段.
- 通过使用DRL框架对四种罕见疾病进行了案例研究:肌肉发育不良,渐进性纤维扩张骨质疏松症,坦吉尔病和异常外周肺动脉狭窄.
主要成果:
- 该DRL框架全面描述了从起源到治疗策略的四种选定的罕见疾病的进展.
- 该DRL的评估期比现有的TRL衍生品更长,从产品前期开发到发布.
- 案例研究表明,DRL能够分析疾病理解和研发进展.
结论:
- 开发的DRL框架提供了一种全面的方法来评估罕见疾病,重点是疾病本身,从发现到药物开发.
- DRL框架可以分析对罕见疾病的理解水平和产品研发的进展.
- 罕见病研究报告 (DRL) 作为一种潜在的指标,可以有效地为罕见疾病分配研发资源.
更多相关视频
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
4.3K
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
7.5K
相关概念视频
01:26Principles of Disease Surveillance
433
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
433
01:20Rheumatic Heart Disease IV: Nursing Management
243
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
243
01:12Relative Risk
1.7K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
1.7K
01:18Steps in Outbreak Investigation
462
In the ever-evolving field of public health, statistical analysis serves as a cornerstone for understanding and managing disease outbreaks. By leveraging various statistical tools, health professionals can predict potential outbreaks, analyze ongoing situations, and devise effective responses to mitigate impact. For that to happen, there are a few possible stages of the analysis:
462
01:26Levels of Health Promotion and Illness Prevention
14.1K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
14.1K
01:28Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K